These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2205095)

  • 21. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).
    Lopez-Fernandez MF; Gonzalez-Boullosa R; Blanco-Lopez MJ; Perez M; Batlle J
    Am J Hematol; 1991 Mar; 36(3):163-70. PubMed ID: 1996556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired von Willebrand disease in monoclonal gammapathies: effectiveness of high-dose intravenous gamma globulin.
    Michiels JJ; van Vliet HH
    Clin Appl Thromb Hemost; 1999 Jul; 5(3):152-7. PubMed ID: 10726000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease.
    Casonato A; Sartori MT; Pontara E; Bertomoro A; Dannhäuser D; Girolami
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):567-73. PubMed ID: 1768767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
    Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease.
    Johnstone IB
    Can Vet J; 1999 Sep; 40(9):645-8. PubMed ID: 10495907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
    Dicke C; Schneppenheim S; Holstein K; Spath B; Bokemeyer C; Dittmer R; Budde U; Langer F
    Ann Hematol; 2016 May; 95(6):945-57. PubMed ID: 27040683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC).
    Ciavarella G; Ciavarella N; Antoncecchi S; De Mattia D; Ranieri P; Dent J; Zimmerman TS; Ruggeri ZM
    Blood; 1985 Dec; 66(6):1423-9. PubMed ID: 3877533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease.
    Tjernberg P; Castaman G; Vos HL; Bertina RM; Eikenboom JC
    Br J Haematol; 2006 May; 133(4):409-18. PubMed ID: 16643449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
    Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
    Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs.
    Meyers KM; Wardrop KJ; Dodds WJ; Brassard J
    Thromb Res; 1990 Jan; 57(1):97-108. PubMed ID: 2105540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cryoprecipitate and plasma on plasma von Willebrand factor multimeters and bleeding time in Doberman Pinschers with type-I von Willebrand's disease.
    Ching YN; Meyers KM; Brassard JA; Wardrop KJ
    Am J Vet Res; 1994 Jan; 55(1):102-10. PubMed ID: 8141483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor.
    Mohri H; Noguchi T; Kodama F; Itoh A; Ohkubo T
    Am J Clin Pathol; 1987 May; 87(5):663-8. PubMed ID: 3107370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.